Bruker Corporation Introduces MALDI Tissuetyper Solution With New High Speed rapifleX MALDI-TOF MS System For Anatomical Pathology Research
ST. LOUIS--(BUSINESS WIRE)--At the 63rd ASMS Conference on Mass Spectrometry & Allied Topics (ASMS), Bruker (NASDAQ: BRKR) announced the launch of the novel MALDI Tissuetyper solution, based on the new rapifleX MALDI-TOF Mass Spectrometry system.
The introduction of the revolutionary rapifleX as the new instrument platform for MALDI imaging anatomical pathology research further enhances Bruker’s leadership position for MALDI-TOF-based applications solutions. The new rapifleX system eliminates many previous bottlenecks in mass spectrometry imaging (MSI), with much improved speed, throughput, ease-of-use, robustness and spatial resolution. At the same time, MSI maintenance efforts are reduced to a minimum by a streamlined design of the ion source for maximum uptime and optimized accessibility.
Help employers find you! Check out all the jobs and post your resume.
The introduction of the revolutionary rapifleX as the new instrument platform for MALDI imaging anatomical pathology research further enhances Bruker’s leadership position for MALDI-TOF-based applications solutions. The new rapifleX system eliminates many previous bottlenecks in mass spectrometry imaging (MSI), with much improved speed, throughput, ease-of-use, robustness and spatial resolution. At the same time, MSI maintenance efforts are reduced to a minimum by a streamlined design of the ion source for maximum uptime and optimized accessibility.
Help employers find you! Check out all the jobs and post your resume.